ArticleDepression and anxiety2023
Edaravone Improved Behavioral Abnormalities, Alleviated Oxidative Stress Inflammation, and Metabolic Homeostasis Pathways in Depression.
Article in Depression and anxiety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The vicious cycle of neuroinflammation and ferroptosis in depression: mechanisms and therapeutic targets.Frontiers in neuroscience · 2026Review
- Promising Potential of Edaravone-Loaded Nanogel in Ameliorating of Stroke in Rats: The Modulation of Immune Response.BioMed research international · 2026Article
- Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats.IBRO neuroscience reports · 2025Article
- Chronic 17β-estradiol treatment improves negative valence, anhedonic profile, and social interactions in ovariectomized, middle-aged female rats.Frontiers in behavioral neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is one of the main factors affecting our daily performance. Among many putative compounds with effect on behavioral and pathophysiological alterations in depression, edaravone (EDV) demonstrates antioxidant and free radical scavenging properties. To investigate possible antidepressive and anxiolytic-like effects of EDV, Wistar rats were randomly divided into six groups: (1) control; (2) EDV (6 mg/kg); (3) post weaning social isolation (PWSI); (4) PWSI+EDV (1.5 mg/kg); (5) PWSI+EDV (3 mg/kg); and (6) PWSI+EDV (6 mg/kg). After the series of behavioral tests, animals were sacrificed, and their hippocampi were dissected for further biochemical and gene expression assays. Our results showed that treatment with 3 and 6 mg/kg EDV after social isolation would improve anxiety, depressive and anhedonic-like behavior in OFT, EPM, FST, and splash tests. In addition, treatment at the aforementioned doses achieved to recover total cellular antioxidant and GSH level. These effects were accompanied with the suppressive effect of EDV on MDA and PCO levels. EDV treatment also modulated the expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.